Si-Bone (NSDQ:SIBN) this week posted third-quarter results that beat the earnings consensus on Wall Street and were in line with revenue estimates.
The Santa Clara, California-based orthopedic implant company reported net losses of $14.2 million, or -41¢ per share, on sales of $26.43 million for the three months ended Sept. 30, for a sales growth of 18.6%. Profit losses were up slightly from Q3 2021 when it reported $15.9 million in losses.
Earnings per share were 7¢ ahead of the Street, where analysts were looking for sales of $26.43 million.
“We are encouraged by the continuing top-line acceleration in our business and the increasing operating leverage we were able to generate in the quarter,” President and CEO Laura Francis said in a news release. “With a record U.S. active surgeon base and growing surgeon enthusiasm for iFuse-Bedrock Granite, I am energized about the long-term potential for the business. As we look beyond 2022, we remain confident th…